CSBio CSBio

X
[{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orion\u2019s Phase 3 REFALS Trial Evaluating Oral Levosimendan in Treatment of ALS Patients Did Not Reach its Pre-Specified Endpoints","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Orion Biotechnology"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Xenon Pharmaceuticals Announces Pricing of $100.0 Million Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Xenon Pharmaceuticals Inc"},{"orgOrder":0,"company":"PharmaTher","sponsor":"CC Biotechnology Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaTher To Develop and Commercialize Novel Wearable Ketamine Delivery Device in Collaboration with CCBIO","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"PharmaTher"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpha Cognition Announces Positive Results from Pivotal Study with ALPHA-1062 in Development for Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Alpha Cognition"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Announces Notice of Allowance for U.S. Patent Covering Ketamine for the Potential Treatment of Parkinson's Disease and Motor Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"PharmaTher"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpha Cognition Announces Positive Topline Results from Bioequivalence Study with ALPHA-1062 in Development for Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Alpha Cognition"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Announces Late-Breaking Abstract Presentation of Positive Efficacy and Safety Data from Phase 1\/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson\u2019s Disease at the MDS International Congress of Parkinson's","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"PharmaTher"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Xiromed","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IntelGenx Receives FDA GDUFA Date for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"IntelGenx"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xenon Pharmaceuticals Announces Launch of XEN1101 Phase 3 Program with Initiation of X-TOLE2 Clinical Trial in Patients with Focal Onset Seizures","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Xenon Pharmaceuticals Inc"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alpha Cognition Announces Withdrawal of Marketed Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Alpha Cognition"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Holdings Provides Update for KETARX (Racemic Ketamine) Development Programs and Expected Milestones for 2023","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"PharmaTher"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","amount":"$6.8 million","upfrontCash":"Undisclosed","newsHeadline":"Alpha Cognition Announces $6.8 Million Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Alpha Cognition"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New Drug Application of KETARX\u2122 (Ketamine) On-Body Pump System","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"PharmaTher"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Spartan Securities LLC","pharmaFlowCategory":"D","amount":"$4.2 million","upfrontCash":"Undisclosed","newsHeadline":"Alpha Cognition Closes First Tranche of Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Alpha Cognition"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alpha Cognition Closes Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Alpha Cognition"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Holdings Announces Update of Type C Meeting with the FDA for KETARX\u2122 (Ketamine) in Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"PharmaTher"},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Acasti Pharma"},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Altasciences Company Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altasciences Completes Clinical Portion of Alzamend Neuro\u2019s Phase IIa Multiple Ascending Dose Clinical Trial for Treatment of Dementia Related to Alzheimer\u2019s","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Altasciences Company Inc"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Xiromed","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IntelGenx Announces Receipt of Complete Response Letter from the FDA for Xiromed-Partnered Buprenorphine Buccal Film","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"IntelGenx"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$6.5 million","upfrontCash":"Undisclosed","newsHeadline":"Alpha Cognition Launches $6.5 Million Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Alpha Cognition"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Vitruvias Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaTher and Vitruvias Enter into Collaboration Agreement for Commercialization of KETARX\u2122 (racemic ketamine) in the U.S.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"PharmaTher"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX\u2122 (racemic ketamine) to the FDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"PharmaTher"},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Acasti Pharma"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$1.3 million","upfrontCash":"Undisclosed","newsHeadline":"Alpha Cognition Announces Initial Closing of Private Placement and Pricing for Continuation of the Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Alpha Cognition"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX\u2122 (Ketamine) to the FDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"PharmaTher"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IntelGenx Provides Regulatory Update for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"IntelGenx"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Announces FDA Acceptance, as a Priority Original Abbreviated New Drug Application, for KETARX\u2122 (Ketamine)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"PharmaTher"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpha Cognition Announces Submission of New Drug Application to the FDA for ALPHA-1062 for Mild-to-Moderate Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Alpha Cognition"},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"Acasti Announces $7.5 Million Private Placement Equity Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Acasti Pharma"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$97.8 million","upfrontCash":"Undisclosed","newsHeadline":"Alpha Cognition Announces Second Closing of Private Placement and Continuation of the Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Alpha Cognition"},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Acasti Pharma"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","amount":"$6.5 million","upfrontCash":"Undisclosed","newsHeadline":"Alpha Cognition Announces Third Closing of Private Placement and Continuation of the Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Alpha Cognition"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Xenon Pharmaceuticals Inc"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$225.0 million","upfrontCash":"Undisclosed","newsHeadline":"Xenon Pharmaceuticals Announces Proposed Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Xenon Pharmaceuticals Inc"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$345.0 million","upfrontCash":"Undisclosed","newsHeadline":"Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Xenon Pharmaceuticals Inc"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$6.5 million","upfrontCash":"Undisclosed","newsHeadline":"Alpha Cognition Announces Amended Terms of Private Placement and Continuation of the Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Alpha Cognition"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Provides Update for Expected FDA Approval of Ketamine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"PharmaTher"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Ketarx (ketamine hydrochloride), is a non-barbiturate, rapid-acting general anesthetic and NMDA receptor antagonist used for induction of anesthesia diagnostic and surgical procedures typically in combination with a muscle relaxant in patients with parkinson’s Disease.

            Lead Product(s): Ketamine Hydrochloride

            Therapeutic Area: Neurology Product Name: Ketarx

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 10, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The net proceeds woll be used for the clinical development of company's XEN1101, a differentiated Kv7 potassium channel opener, as well as other programs entering clinical development and to fund its pre-clinical and discovery activities.

            Lead Product(s): XEN1101

            Therapeutic Area: Neurology Product Name: XEN1101

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: J.P. Morgan

            Deal Size: $345.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering December 04, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.

            Lead Product(s): Galantamine Benzoate

            Therapeutic Area: Neurology Product Name: ALPHA-1062

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $6.5 million Upfront Cash: Undisclosed

            Deal Type: Private Placement December 04, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The net proceeds woll be used for the clinical development of company's XEN1101, a differentiated Kv7 potassium channel opener, as well as other programs entering clinical development and to fund its pre-clinical and discovery activities.

            Lead Product(s): XEN1101

            Therapeutic Area: Neurology Product Name: XEN1101

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: J.P. Morgan

            Deal Size: $300.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering November 29, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The net proceeds woll be used for the clinical development of company's XEN1101, a differentiated Kv7 potassium channel opener, as well as other programs entering clinical development and to fund its pre-clinical and discovery activities.

            Lead Product(s): XEN1101

            Therapeutic Area: Neurology Product Name: XEN1101

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: J.P. Morgan

            Deal Size: $225.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering November 29, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.

            Lead Product(s): Galantamine Benzoate

            Therapeutic Area: Neurology Product Name: ALPHA-1062

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Spartan Capital Securities

            Deal Size: $6.5 million Upfront Cash: Undisclosed

            Deal Type: Private Placement November 08, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            GTX-104 is a clinical stage, novel formulation of nimodipine being developed for IV infusion in aneurysmal Subarachnoid Hemorrhage patients. It incorporates surfactant micelles as the drug carrier to solubilize nimodipine.

            Lead Product(s): Nimodipine

            Therapeutic Area: Neurology Product Name: GTX-104

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 23, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The Company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.

            Lead Product(s): Galantamine Benzoate

            Therapeutic Area: Neurology Product Name: ALPHA-1062

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $97.8 million Upfront Cash: Undisclosed

            Deal Type: Private Placement October 16, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Ketarx™ (ketamine hydrochloride), is a non-barbiturate, rapid-acting general anesthetic and NMDA receptor antagonist used for induction of anesthesia diagnostic and surgical procedures typically in combination with a muscle relaxant in patients with parkinson’s Disease.

            Lead Product(s): Ketamine Hydrochloride

            Therapeutic Area: Neurology Product Name: Ketarx

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 27, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            ALPHA-1062, a proprietary, patented, delayed release oral tablet formulation in development for the treatment of mild-to-moderate Alzheimer’s Disease.

            Lead Product(s): Galantamine Benzoate

            Therapeutic Area: Neurology Product Name: ALPHA-1062

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 27, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY